Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489515 · ClinicalTrials.gov registry record
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
A clinical trial of Colorectal Cancer and Pancreatic Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 115
- Enrollment target
- 1
- Study location
NCT00489515 is a study of Colorectal Cancer and Pancreatic Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 115 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00489515, a study of Colorectal Cancer and Pancreatic Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue, may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and find out how far the disease has spread. PURPOSE: This clinical trial is studying the side effects and how well visceral lymphatic mapping using isosulfan blue works in patients with cancer of the pancreas, colon, stomach, small intestine, or gallbladder.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 1999-02 |
| Est. Completion | 2010-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00489515
The ClinicalTrials.gov registry entry for NCT00489515 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00489515 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00489515 about?
NCT00489515 is a clinical study titled "Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder". RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue, may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and find out how far the disease has spread. PURPOSE: This clinical trial is studying the side effects and how well viscer...
What is the current status of trial NCT00489515?
This trial is currently completed. The enrollment target is 115 participants. The study started on 1999-02. Estimated completion is 2010-08.
What conditions does trial NCT00489515 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Small Intestine Cancer, Gallbladder Cancer.
Who is sponsoring clinical trial NCT00489515?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489515 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.